Award Ceremony | TOP101 Innovative Pharmaceutical Enterprises

On September 4, the award ceremony for the 2026 Pharmaceutical Industry TOP101 and 11 Core Industry Chain Lists was grandly held. With its strong R&D strength, pipeline layout, and international BD achievements, Xuanzhu Biopharma was successfully selected for the 2026 TOP101 Innovative Pharmaceutical Enterprises list.

This list was launched by Yaorongquan, strictly selecting the leading forces with the greatest innovation strength and development prospects from five dimensions: R&D pipeline value, revenue growth potential, BD transaction achievements, commercialization expansion progress, and capital market recognition. Being selected for this list is the industry's recognition of the company's innovation capability and development potential.

Xuanzhu Biopharma Successfully Selected for the 2026 TOP101 Innovative Pharmaceutical Enterprises >>>

As a pharmaceutical company driven by independent innovation, through years of innovation accumulation, Xuanzhu Biopharma has built a technology platform system covering multiple fields such as small molecules, large molecules, small nucleic acids, and AI pharmaceuticals, focusing on major disease areas such as oncology, digestion, and metabolism. Multiple self-developed innovative drugs have successfully achieved commercialization, while overseas licensing cooperation continues to be advanced, accelerating the entry of domestic innovative drugs into the global market.

In the future, Xuanzhu Biopharma will adhere to source innovation, focus on unmet clinical needs, continue to develop high-quality innovative drugs, and help promote the high-quality development of the domestic biopharmaceutical industry.

About Xuanzhu Biopharma

Xuanzhu Biopharma (Stock Code: 02575.HK) is an innovative pharmaceutical company rooted in China with a global vision, focusing on major disease areas such as digestion, oncology, and metabolism, and dedicated to the R&D, production, and commercialization of Class 1 new drugs with core independent intellectual property rights. As an emerging commercialization-oriented innovative drug company driven by R&D and empowered by AI, the company has built a technology system with coordinated interaction among a small molecule drug R&D platform, a biologics R&D platform, and an AI drug R&D platform, thereby forming a product pipeline rare in China that simultaneously covers multiple types such as small molecule chemical drugs, large molecule biologics, and antibody-drug conjugates. Guided by unmet clinical needs, the company is committed to developing into a first-class innovative drug enterprise with independent R&D, production, and sales capabilities.